History

Many minds, better together.

Our multidisciplinary team is keen to bring your valued molecule in the clinics.

2018 Ardena Group acquires Syntagon
Ardena acquires Scandinavian company Syntagon and strengthens its drug substance service offering. Drug substance batch sizes up to 100 kg can be produced. The 30-strong Syntagon team also adds specialist expertise in GMP chromatographic purification processes to our group.
2018 Ardena Group acquires Chemconnection
Ardena acquires Chemconnection, adding drug substance and nanomedicine expertise. Based at the Pivot Park life sciences campus in Oss, the Netherlands, ChemConnection employs a team of more than 60 with expertise in process and analytical development, cGMP manufacturing and stability studies for Drug Substances and nanomedicines. Its state-of-the-art facility has the capability to manufacture active ingredients up to 30 kg scale.
2017 Ardena Group acquires ABL
The acquisition of Netherlands based ABL broadens our preclinical and clinical offering to include bioanalytical and drug discovery services.
The 60-strong ABL team specializes in the analysis of endogenous (biomarkers) and exogenous compounds (drugs) in biological matrices derived from humans and animals. ABL is active in all phases of drug development, including discovery, pre-clinical and clinical phases.
2017 Launch of the Ardena brand
Ardena is launched as the new brand for our services. The Ardena name reveals the increased service offering and complementary capabilities of the former companies, Pharmavize and Crystallics. Our logo resembles a compass and symbolizes Ardena’s navigational skills. During the drug development journey, we point, with minimized risk, our customers in the best direction.
2016 Acquisition of Crystallics
Netherlands based Crystallics is the first company that joins Pharmavize in executing its vertical integration strategy. Crystallics is specialized in the identification, characterization and selection of the physical forms of drug substances. The company is a pioneer in the field of solid-state research and developed unique and proprietary technologies.
2015 Mentha Capital invests in Pharmavize
Pharmavize, a Belgium based CDMO specialized in drug and dossier development, engages private equity company Mentha Capital and starts executing an M&A strategy to become a leading, one-source and fully integrated contract developer of investigational drugs.